Document is current

Any future updates will be listed below

Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States

Crossref DOI link: https://doi.org/10.1007/s13555-018-0251-4

Published Online: 2018-07-13

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark